NGNE vs TSHA
NGNE: Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating neurological diseases. TSHA: Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous system, with a primary focus on Rett syndrome.
Side-by-side fundamentals
| Metric | NGNE | TSHA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $36.11 | $5.66 | |
| Market cap as of 2026-07-23 | $721M | $1.8B | |
| PEG as of 2026-07-23 | -1.00 | -1.30 | TSHA lower |
| Net margin as of 2026-07-23 | -8123.7% | -780.3% | TSHA higher |
| Operating margin as of 2026-07-23 | -8930.3% | -782.5% | TSHA higher |
| ROE as of 2026-07-23 | -25.3% | -56.1% | NGNE higher |
| ROA as of 2026-07-23 | -23.3% | -40.2% | NGNE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.23 | NGNE lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +3.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +57.5% | |
| Beta as of 2026-07-23 | 1.67 | 1.26 | |
| 1-year return as of 2026-07-22 close | +64.6% | +124.1% | TSHA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.